Bullfrog AI Holdings, Inc. (BFRG) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Bullfrog AI Holdings, Inc. is an emerging growth company and smaller reporting company focused on using Artificial Intelligence and Machine Learning (AI/ML) to analyze complex data sets for drug development and precision medicine. The company operates through its proprietary platform, bfLEAP™, and holds various licensing agreements with academic institutions including Johns Hopkins University (JHU) and George Washington University.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $65,000 | $0 | $65,000 |
| Net Loss | $(1,763,464) | $(1,252,978) | $(5,278,904) | $(4,058,923) |
| Operating Expenses | $1,819,941 | $1,363,944 | $5,467,622 | $4,091,559 |
| Cash and Equivalents (End of Period) | $4,238,988 (as of Sept 30, 2024) | |||
| Total Liabilities | $779,037 (as of Sept 30, 2024) | |||
| Stockholders' Equity | $3,823,169 (as of Sept 30, 2024) |
Note: The company reported zero revenue for the nine months ended September 30, 2024, compared to $65,000 in the same period in 2023.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero in Q3 2024 and the YTD period, down from $65,000 in Q3 2023. The company has not yet generated significant recurring revenue.
- Increased Operating Costs: Total operating expenses increased by approximately 34% in Q3 2024 ($1.82M) compared to Q3 2023 ($1.36M). YTD expenses rose by roughly 34% to $5.47M. This increase is attributed to hiring additional technical staff, a Chief Science Officer, and increased stock-based compensation.
- Liquidity Improvement: Cash and cash equivalents increased from $2.62M at year-end 2023 to $4.24M at September 30, 2024, driven by financing activities.
- Debt Structure: The company has no long-term debt. Current liabilities include $172,005 in short-term insurance financing and $515,658 in accrued expenses (up from $80,694 in 2023), largely due to accrued minimum royalty payments to JHU-APL.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current capital resources, bolstered by a $2.7M net proceeds from a registered direct offering in October 2024 (subsequent event), are sufficient to fund operations into the fourth quarter of 2025. However, the company will require additional capital to continue its strategy.
- Strategic Focus: The company is focusing on target discovery using proprietary data sets (e.g., Lieber Institute partnership) and advancing in-licensed drug assets (e.g., Mebendazole formulations, siRNA programs). They aim to monetize through strategic partnerships or by rescuing late-stage failed drugs.
- Internal Control Weaknesses: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, due to material weaknesses in internal controls over financial reporting. Remediation efforts are ongoing, including transitioning to an enterprise accounting platform and hiring a Corporate Controller.
- Risks: Key risks include the inability to raise additional capital, failure to generate revenue from partnerships, and the high cost of R&D without near-term commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.2M cash balance plus the $2.7M October 2024 proceeds against the burn rate of ~$1.7M per quarter to confirm the Q4 2025 runway estimate.
- Revenue Pipeline: Investigate the status of the "first commercial service contract" mentioned in the overview and the timeline for monetizing the Lieber Institute data partnership.
- Royalty Obligations: Confirm the accrual of the $300,000 annual minimum royalty payment to JHU-APL for 2024 and the impact on future cash flow.
- Internal Controls: Monitor the progress of remediation efforts regarding the material weaknesses in financial reporting controls.
- Dilution Risk: Review the impact of outstanding warrants (approx. 5.6M) and options (approx. 850k) on future share count and potential dilution from future fundraising.